Business
Corvus Pharmaceuticals Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
SITC presentation builds on data at ASCO in June, adding evidence supporting a new immuno-oncology approach with CPI-006 via activation of immune cells and
About this update from Corvus Pharmaceuticals, Inc.
[{"type":"text","content":" SITC presentation builds on data at ASCO in June, adding evidence supporting a new immuno-oncology approach with CPI-006 via activation of immune cells and the inhibition of adenosine production\n Company also presents data supporting potential of Adenosine Gene Signature to serve as a biomarker to identify patients that are likely to respond to CPI-006 and ciforadenant Company to host investor and analyst reception today at 6:00 pm ET BURLINGAME, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, today announced updated results from its Phase 1/1b trial of CPI-006, the Company’s anti-CD73 antibody. The clinical data continue to support a novel mechanism of action involving the activation of immune cells potentially directed against tumors, along with the inhibition of adenosine production. The results will be presented today in an oral session at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Maryland by Jason J. Luke, M.D., principal investigator of the trial and Director of the Cancer Immunotherapeutics Center at UPMC Hillman Cancer Center and Associate Professor of Medicine at the University of Pittsburgh School of Medicine. “As previously reported at ASCO, our clinical studies continue to demonstrate the novel immunobiological properties of CPI-006,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. “Based on its ability to activate various immune cells and inhibit the production of adenosine, we believe CPI-006 has potential as a monotherapy and combination medicine for a variety of tumor types. We plan to continue to enroll cancer patients in the CPI-006 Phase 1/1b study at the selected dose of 18 mg/kg, which has been well-tolerated to date and has demonstrated complete occupancy of the target within tumors. In addition, we continue to develop the Adenosine Gene Signature, with additional data from a larger number of patients with renal cell cancer indicating that it could be used as a biomarker driven patient enrichment strategy in future clinical trials which would potentially enable us to select patients most likely to benefit from ...